The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics
Open accessAbstract
Abstract Pharmaceutical industry and the art and science of drug development are sorely in need of novel transformative technologies in the current age of digital health and artificial intelligence (AI). Often described as game-changing technologies, AI and machine learning algorithms have slowly but surely begun to revolutionize pharmaceutical industry and drug development over the past 5 years. In this expert review, we describe the most frequently used machine learning algorithms in drug development pipelines and the -omics databases well poised to support machine learning and drug discovery. Subsequently, we analyze the emerging new computational approaches to drug discovery and the in silico pipelines for drug repositioning and the synergies among -omics system sciences, AI and machine learning. As with system sciences, AI and machine learning embody a system scale and Big Data driven vision for drug discovery and development. We conclude with a future outlook on the ways in which machine learning approaches can be implemented to buttress and expedite drug discovery and precision medicine. As AI and machine learning are rapidly entering pharmaceutical industry and the art and science of drug development, we need to critically examine the attendant prospects and challenges to benefit patients and public health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many more examples are available [3,32,33,34,35,36,37], showing that AI-based methods can accelerate the drug discovery process and enable the development of more effective medications.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mining association rules between sets of items in large databases
Agrawal, R., Imieliński, T., & Swami, A. (1993) · ACM SIGMOD Record · doi:10.1145/170036.170072 · Cited by 4,551
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1951 · Cited by 2,673
Bias in error estimation when using cross-validation for model selection
Varma, S., & Simon, R. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-91 · Cited by 2,485 · cited 1×
“Then, the procedure is repeated as many times as the data points (Baek et al., 2009; Varma and Simon, 2006).”
Machine learning applications in genetics and genomics
Libbrecht, M. W., & Noble, W. S. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3920 · Cited by 2,250
Assessing the accuracy of prediction algorithms for classification: an overview
Baldi, P., Brunak, S., Chauvin, Y., Andersen, C. A. F., & Nielsen, H. (2000) · Bioinformatics · doi:10.1093/bioinformatics/16.5.412 · Cited by 2,111
Research works printed but not linked: 7
- Azuaje F. (2017). Computational models for predicting drug responses in cancer research. Brief Bioinform, 18, 820–829.
- Jang IS, , Neto EC, , Guinney J, , Friend SH, , and Margolin AA. (2014). Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pac Symp Biocomput, 2014:63–74.
- Kuo M.-H, , Kushniruk A, , Borycki EM, , and Greig D. (2009). Application of the Apriori algorithm for adverse drug reaction detection. Stud Health Technol Inform, 148, 95–101.
- Neto EC, , Jang IS, , Friend S. H, , and Margolin AA. (2014). The Stream algorithm: Computationally efficient ridge-regression via Bayesian model averaging, and applications to pharmacogenomic prediction of cancer cell line sensitivity. Pac Symp Biocomput, 2014, 27–38.
- Nguyen L, , Dang C, , and Ballester PJ. (2016). Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. F1000Research, 5, ISCB Comm. J-2927.
- Zhao K, , and So H. (2017). A machine learning approach to drug repositioning based on drug expression profiles: Applications to schizophrenia and depression/anxiety disorders. arXiv
- Zou J, , Zheng M.-W, , Li G, , and Su Z.-G. (2013). Advanced systems biology methods in drug discovery and translational biomedicine. Biomed Res Int, 2013, 1–8. · DOI
Cited by
Sorted by citations
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
The role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347
Artificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M. J. V., & Aittokallio, T. A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 229
Selvaraj, C., Chandra, I., & Singh, S. K. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10326-z · Cited by 220
Metadata
- Authors
- Koromina, M., Pandi, M.-T., & Patrinos, G. P.
- Affiliations
- University of Patras (GR)
- Corresponding author
- Patrinos, George P.
- Venue
- OMICS A Journal of Integrative Biology
- Publisher
- SAGE Publications
- Published
- 2019-11
- Volume
- 23
- Issue
- 11
- Pages
- 539-548
- ISSN
- 1536-2310 (ISSN-L)
- 1557-8100
- OpenAlex
- W2981458781
- Cited by
- 140
- References
- 74
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 25 · 2023: 23 · 2022: 21 · 2021: 16 · 2020: 13
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- OMICS A Journal of Integrative Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Keywords
- drug repurposing, drug development, artificial intelligence, machine learning, omics databases, computational drug discovery, precision medicine, big data, pharmaceutical industry
- MeSH terms
- Machine Learning, Algorithms, Artificial Intelligence, Models, Theoretical, Reproducibility of Results, Computational Biology, Genomics, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
